[ADVANCED AGING CARE WITH EGF-POWERED ENCAPSULATED ACTIVES] A concentrated ampoule powered by EGF and enhanced with 13 peptides and 18K gold, featuring visible melting silk-texture actives to deliver advanced firming care and help support smoother-looking, more supple, and refined skin [VISIBLE FIRM-LOOKING FOR SILKY-SMOOTH SKIN] Silk Peptides, EGF, and a 13-peptide complex help improve the appearance of elasticity while smoothing the look of fine lines for a firmer-looking complexion [MELTING GOLD-INFUSED FORMULA FOR VISIBLE VOLUME] 24K Gold-infused actives melt into skin to support fuller-looking contours and smoother skin texture with a radiant, silky finish [MULTI-COLLAGEN DENSITY SUPPORT WITH EGF CARE] A collagen blend with Deep Collagen and EGF helps improve the look of firmness and skin density while supporting a more refined-looking skin texture [PRECISION DOSAGE APPLICATOR FOR CONTROLLED USE] Designed with a precision dosage applicator that helps dispense the desired amount cleanly for targeted facial application and controlled daily skincare use
Its useful to know
As with any treatment, however, there can be potential side effects to consider
Asian J Gerontol Geriatr 6(2):8287 Kancherla V et al (2017) Long-term metformin therapy and monitoring for vitamin B12 deficiency among older veterans
IGF-1 LR3 vs IGF-1 DES (1-3) vs HGH (Somatropin) vs Mecasermin (Native rhIGF-1) Feature Type IGF-1 LR3 Synthetic IGF-1 analog IGF-1 DES (1-3) Truncated IGF-1 variant HGH (Somatropin) Recombinant growth hormone Mecasermin (Increlex) Recombinant native human IGF-1 Feature Amino acids IGF-1 LR3 83 IGF-1 DES (1-3) 67 HGH (Somatropin) 191 Mecasermin (Increlex) 70 (identical to endogenous IGF-1) Feature Half-life IGF-1 LR3 20-30 hours IGF-1 DES (1-3) ~20-30 minutes HGH (Somatropin) 2-3 hours Mecasermin (Increlex) ~5.8 hours Feature Receptor potency IGF-1 LR3 ~3x native IGF-1 IGF-1 DES (1-3) ~10x native IGF-1 (locally) HGH (Somatropin) Indirect (drives endogenous IGF-1) Mecasermin (Increlex) 1x (it is native IGF-1) Feature Action IGF-1 LR3 Systemic, long-acting IGF-1 DES (1-3) Localized, rapid HGH (Somatropin) Systemic upstream cascade Mecasermin (Increlex) Systemic, replacement therapy Feature Dosing frequency IGF-1 LR3 Once daily IGF-1 DES (1-3) 2-3x daily HGH (Somatropin) 1-2x daily Mecasermin (Increlex) Twice daily SubQ Feature Common dose context IGF-1 LR3 20-100 mcg/day (research) IGF-1 DES (1-3) 50-150 mcg/day split (research) HGH (Somatropin) 2-8 IU/day (research) Mecasermin (Increlex) 0.04-0.12 mg/kg twice daily (clinical) Feature IGFBP binding IGF-1 LR3 Very low IGF-1 DES (1-3) Very low HGH (Somatropin) N/A (acts upstream) Mecasermin (Increlex) Normal (full IGFBP affinity) Feature FDA status IGF-1 LR3 Not approved IGF-1 DES (1-3) Not approved HGH (Somatropin) FDA-approved (multiple indications) Mecasermin (Increlex) FDA-approved (pediatric severe primary IGFD) Feature WADA status IGF-1 LR3 Prohibited IGF-1 DES (1-3) Prohibited HGH (Somatropin) Prohibited Mecasermin (Increlex) Prohibited Feature Practical note IGF-1 LR3 Long-acting IGF-1 analog with the most accumulated community data IGF-1 DES (1-3) Localized, rapid signaling
DNA synthesis is essential for these processes, as it provides the genetic material necessary for cell division and differentiation
